Konten disusun AI — bisa keliru. Baca disclaimer lengkap
Sentimen Publik
Pear Therapeutics, Inc.
Sentimen mengukur persepsi publik, bukan fakta hukum. Baca metodologi untuk batasan dan bias yang diakui.
Pemberitaan media teknologi kesehatan (STAT News, Fierce Biotech, MedTech Dive, MobiHealthNews) dominan membingkai Pear sebagai 'pelopor yang gagal secara komersial': mengakui pencapaian regulasi bersejarah (FDA pertama untuk DTx) namun kritis terhadap model bisnis, valuasi SPAC yang berlebihan, dan kegagalan memecahkan reimbursmen. Campuran penghormatan atas inovasi dan kritik analitis atas eksekusi.
CEO Corey McCann bersikap reflektif dan terbuka saat mengumumkan kebangkrutan ('not the outcome I envisioned when I founded Pear in 2013'), menyalahkan kondisi pasar dan reimbursmen. Nada manajemen campuran antara kekecewaan pribadi dan rasionalisasi eksternal — hadir sebagai suara minoritas yang jujur. McCann kemudian membeli kembali sebagian aset via Harvest Bio, menunjukkan komitmen pada misi.
Lebih dari 250 karyawan terdampak PHK selama 2022–2023 (puncaknya 170 sekaligus pada April 2023). Pesangon hanya dua minggu gaji. Pasien kehilangan akses ke terapi digital untuk adiksi dan insomnia. Sentimen karyawan dominan negatif — seorang karyawan menyatakan ke media: 'The mood around here today is not great.' Pasien juga terdampak gap layanan sebelum PursueCare/Nox Health mengambil alih.
FDA tidak mengeluarkan pernyataan publik tentang kebangkrutan Pear. Posisi regulasi tetap konsisten: FDA telah menyetujui produk berdasarkan bukti klinis dan tidak terlibat dalam keberhasilan komersial. CMS mulai memperbarui kode reimbursmen DTx pada 2024–2025, sebagian berkat kerja advokasi Pear — tetapi terlambat untuk menyelamatkan perusahaan.
Komunitas digital health, health tech investor, dan profesional di LinkedIn/Twitter bereaksi dengan campuran sentimen: kesedihan atas hilangnya pelopor DTx, kritik terhadap model SPAC dan valuasi berlebihan, dan perdebatan apakah kebangkrutan Pear berarti 'kematian DTx' atau hanya kegagalan satu perusahaan. Beberapa praktisi industri menulis analisis panjang menyangkal bahwa Pear = DTx ('9 reasons why Pear's bankruptcy doesn't spell doom for DTx').
Kutipan Terpilih
“Today is a difficult day for Pear Therapeutics. We announced that Pear voluntarily filed for Chapter 11 and will seek to sell assets through a sales process. We also announced a reduction in force, including me. This is certainly not the outcome I envisioned when I founded Pear in 2013.”
Pernyataan publik McCann saat mengumumkan kebangkrutan dan pengunduran dirinya.
“Less than two years after Pear Therapeutics went public in a SPAC deal worth $1.6 billion, its assets were sold in an auction for just over $6 million.”
Kontras dramatis antara valuasi SPAC dan harga jual aset.
“Pear Therapeutics lost 99.28% of its value resulting from the SPAC merger with Thimble Point Acquisition Corp. Investors have unfortunately lost 75% over the last year alone.”
Dampak finansial bagi investor publik.
“The mood around here today is not great.”
Reaksi karyawan saat gelombang PHK kedua (November 2022, 22% tenaga kerja).
“Pear failed to commercialise their existing products, created an unsustainable cost base and over-invested in R&D. Intriguing technology is not enough to ensure that DTx companies are successful.”
Analisis post-mortem yang mengidentifikasi akar masalah: gap antara inovasi dan komersialisi.
“Pear's bankruptcy and ultimate dismantling have sent shockwaves through the industry and laid bare persistent challenges facing the DTx sector.”
Dampak kebangkrutan Pear terhadap sentimen industri DTx secara keseluruhan.
“Pear's trailblazing efforts in regulatory advancements and market presence have had a lasting impact on the future direction of DTx. Their achievements have paved the way for other DTx companies to follow suit.”
Pengakuan atas kontribusi positif Pear meski perusahaan gagal.
“Reimbursement is crucial to success, especially when designing prescriptive DTx that are relatively expensive in comparison to cheaper nonprescriptive DTx options.”
Identifikasi akar masalah utama: reimbursmen.
“Pear Therapeutics went public via SPAC at a valuation of US$1.6B — a whopping four hundred times their 2021 revenue. Just twenty four months later, Pear filed for bankruptcy.”
Analisis yang menyoroti absurditas valuasi SPAC relatif terhadap pendapatan riil.
“Pear Therapeutics filed for Chapter 11, terminated 170 employees — approximately 92% of its workforce — and continued to operate in limited capacity with 15 employees.”
Skala PHK massal: dari 185 menjadi 15 karyawan.
“Sandoz's decision to exit the co-promotion agreement stems from its transformation and subsequent leadership change, which has resulted in a reinforced focus on and capital allocation for Sandoz' core business.”
Alasan resmi Sandoz mengakhiri kemitraan — diformulasikan netral tapi berdampak besar pada Pear.
“PursueCare acquired Pear's FDA-cleared reSET and reSET-O apps and is relaunching them for patients with addiction. The treatments get a second life a year after bankruptcy.”
Inovasi Pear bertahan melampaui kebangkrutan perusahaan.
“Pear's bankruptcy could be emblematic of a larger problem in health tech: companies that are developing novel treatments or technologies may find themselves unable to generate sufficient revenue if the healthcare system is slow to adapt.”
Menempatkan Pear dalam konteks masalah sistemik health tech yang lebih luas.
“The field is entering a more stable, evidence-led phase. Regulators understand it better. Payers are more receptive. Real success requires three things: rigorous evidence, regulatory alignment, and viable reimbursement pathways.”
Optimisme bahwa industri DTx belajar dari kegagalan Pear dan menuju fase lebih matang.